Evaluation Of The Reproductive And Developmental

Toxicities Of The Aqueous Extract Of

Labisia Pumila Var. Alata In Female Rats by Mohd Puad @ Mohd Fuad, Wan Ezumi
EVALUATION OF THE REPRODUCTIVE AND DEVELOPMENTAL 
TOXICITIES OF THE AQUEOUS EXTRACT OF 
Labisia pumila var. alata IN FEMALE RATS 
by 
WAN EZUMI BINII MOHD PUAD @ MOHO FUAD 
Thesis submitted in fulfilment of the 
requirements for the degree of 
Doctor of Philosophy 
October 2009 
DECLARATION 
I declare that the contents presented in this thesis are my own work, which was 
done at School of Medical Sciences, Universiti Sains Malaysia unless stated 
otherwise. The thesis has not been previously submitted for any other degree. 
ACKNOWLEDGEMENTS 
Dengan nama Allah Yang Maha Pengasih /agi Maha Penyayang 
Alhamdulillah setinggi-tinggi kesyukuran dirafa'kan ke hadrat Allah SWT 
kerana dengan limpah rahmat dan inayahnya telah memberikan saya kekuatan, 
ketabahan dan keyakinan untuk menyiapkan kajian dan tesis ini. Sekalung 
penghargaan dan jutaan terima kasih saya tujukan kepada kedua-dua penyelia 
saya, Prof. Syed Mohsin Sahil Jamalullail dan Prof. Madya Dr. Siti Amrah 
Sulaiman serta penyelia bersama, Dr. Mohd Suhaimi Abdul Wahab yang tidak 
pernah jemu memberikan tunjuk ajar serta nasihat dan kritikan yang membina 
di sepanjang saya menjalankan kajian ini. Ucapan penghargaan seterusnya 
dikhaskan kepada Universiti Sains Malaysia yang menaja dan membiayai 
pengajian saya melalui Skim Rancangan Latihan Kakitangan Akademik dan 
terdahulu Skim Pasca Siswazah. Juga tidak ketinggalan, setinggi-tinggi 
penghargaan kepada Geran Penyelidikan IRPA RM-8 tajaan Kementerian 
Sains Teknologi dan Innovasi yang membiayai kajian ini. 
Terima kasih yang tidak terhingga juga ditujukan kepada Prof. Madya Dr. 
Syed Hatim Noor dan Dr. Kamarul Imran Musa yang telah memberikan 
panduan di dalam analisis statistik, Prof. Madya Dr. Hasnan Jaafar di atas 
tunjuk ajar dan pemeriksaan kajian histopatologi, Prof. Madya Dr. Farid Che 
Ghazali di atas penyeliaan kajian elektron mikroskop serta Mr. S 
Pannerchelvam dan Dr. Sarina Sulong di atas keprihatinan dan bantuan beliau 
memer-iksa kandungan tesis ini. Seterusnya, segala bantuan akademik dan 
teknikal yang dicurahkan oleh En. Lukmi Ismail, Puan Roslina Mat Zain, En. 
II 
Ruzman Mohd Nor, En. Harisal, ahli-ahli kumpulan Penyelidikan Perubatan 
Herba dan Reproduktif Toksikologi, kakitangan Makmal Bioperubatan PPSK, 
Unit Rumah Haiwan USMKK (LARU), Unit Fotografi PPSP, Jabatan Immunologi 
PPSP, Unit Elektron Mikroskopi UKM dan semua pensyarah serta kakitangan 
Jabatan Farmakologi PPSP amatlah dihargai. 
Teristimewa saya ingin merakamkan terima kasih yang tidak terhingga 
kepada suami tercinta, Mohd Anizan Bakhtiar b. Abdullah yang banyak 
menghulurkan bantuan teknikal dan tunjuk ajar kepada saya di dalam 
menjalankan kerja-kerja penyelidikan serta sokongan moral yang tidak berbelah 
bahagi di sepanjang saya mengharungi pengajian dan kehidupan di alam 
kampus ini. Buat anak sulung tersayang Irsyad Rizqy, keletah dan 
kemanjaannya amat menghiburkan dan menguatkan semangat saya saban 
hari. Kepada kedua ibu bapa tersayang, ayahanda Mohd Fuad b. Abdul 
Rahman dan bonda Wan Kamariah bt. Wan Daud, adinda-adinda serta saudara 
mara yang dikasihi, segala doa, pengorbanan dan sokongan ikhlas kalian akan 
dikenang sehingga ke akhir hayat. Buat rakan-rakan seperjuangan di PPSP, 
PPSK dan PPSG terima kasih diucapkan di atas persahabatan yang dihulurkan 
yang memberikan saya kekuatan di dalam mengharungi kehidupan bergelar 
pelajar ijazah lanjutan ini. 
Akhir kata, semoga kajian dan tesisini dapat memberi manfaat kepada 
semua. Mudah-mudahan segala penat lelah dan pengorbanan kita mendapat 
keberkatan daripada Allah SWT. 
iii 
TABLE OF CONTENTS 
ACKNOWLEDGEMENTS 
TABLE OF CONTENTS 
LIST OF TABLES 
LIST OF FIGURES 
LIST OF PLATES 
LIST OF SYMBOLS AND ABBREVIATION 
ABSTRAK 
ABSTRACT 
CHAPTER ONE: INTRODUCTION 
1.1 Preface 
1.2 Reproductive and developmental toxicology 
1.3 Herbal medicine 
1.3.1 Safety issue of herbal medicine 
1.3.2 Labisia pumila (Blume) Fern.-Vill 
1.4 Scope of the study 
1.4.1 Test procedures and guidelines used 
1.5 Objectives 
1.5.1 General objectives 
1.5.2 Specific objectives 
1.6 Importance of the study 
CHAPTER TWO: LITERATURE REVIEW 
2.1 Medicinal plants in Malaysia 
Page 
ii 
iv 
XI 
xiii 
xiv 
xvi 
xix 
xxi 
1 
1 
3 
5 
8 
11 
14 
16 
17 
17 
17 
19 
21 
21 
2.2 Research and development of herbal medicine in Malaysia 25 
2.3 Detailed information on Labisia pumila 30 
2.3.1 General description 
2.3.2 Botanical characteristic 
iv 
30 
30 
2.3.3 Traditional and commercial herbal preparation 33 
2.3.4 Chemical constituents 34 
2.3.5 Biological activities 35 
2.3.6 Ethnobotanical research 36 
2.3.7 Toxicity and side effects 37 
2.4 Evaluation and regulation of herbal medicine products in 40 
Malaysia 
2.4.1 Preclinical safety and toxicity assessment of new 41 
herbal drugs 
2.4.2 Clinical trials 42 
2.5 Regulatory guidelines for reproductive and developmental 43 
toxicology 
2.5.1 The WHO General Guidelines for Methodologies on 44 
Research and Evaluation of Traditional Medicine 
2.5.2 The OECD Guidelines for the Testing of Chemicals 45 
2.5.3 The U.S FDA Redbook 2000: Toxicological Principles 47 
for the Safety Assessment of Food Ingredients 
2.5.4 The ICH Guidelines for Detection of Toxicity to 49 
Reproduction for Medicinal Products 
2.6 Use of animals in reproductive and developmental 52 
toxicology research 
2.6.1 I ntrod uction 52 
2.6.2 Biological features of reproductive system of female 55 
rats 
CHAPTER THREE: MATERIALS AND METHODS 60 
3.1 Preliminary Study on the Effects of Aqueous Extract of LPA 60 
on Teratogenicity in Rats 
3.1.1 Objectives 
3.1.2 Research and ethical committee approval 
3.1.3 Chemicals and experimental equipments 
3.1.4 Plant materials 
3.1.4.1 Plant extraction 
3.1.4.2 Dosage preparation 
3.1.4.2.1 Dosage calculation 
v 
60 
60 
60 
61 
61 
64 
65 
3.1.5 Animals 67 
3.1.5.1 Housing and identification 67 
3.1.6 Experimental protocol 68 
3.1.6.1 Vaginal smear and determination of oestrous 68 
cycle 
3.1.6.2 Mating procedures and determination of 69 
pregnancy 
3.1.6.3 Dose administration 69 
3.1.6.4 General observation and behavioural 70 
changes of animals 
3.1.6.5 Termination of animals 70 
3.1.6.6 Gross examination of animals 71 
3.1.6.7 Parameters of study 73 
3.1.7 Statistical analysis 75 
3.2 Main Study I: Evaluation of the Teratogenicity of Biolabisia® 79 
in Rats 
3.2.1 Objectives 79 
3.2.2 Chemicals and experimental equipments 79 
3.2.3 Research and ethical committee approval 79 
3.2.4 Plant materials 79 
3.2.4.1 Plant extraction 80 
3.2.4.2 Dosage preparation 81 
3.2.4.2.1 Dosage calculation 81 
3.2.5 Animals 82 
3.2.6 Experimental protocol 82 
3.2.6.1 Histopathology of reproductive organs 83 
3.2.6.1.1 Fixation 83 
3.2.6.1.2 Processing of tissue samples 84 
3.2.6.1.3 Paraffin wax embedding 84 
3.2.6.1.4 Section cutting 85 
3.2.6.1.5 Staining 86 
3.2.6.1.6 Slide evaluation 87 
3.2.6.2 Parameters of study 88 
3.2.7 Statts-tical analysis 91 
vi 
3.3 Main Study II: Evaluation of the Female Reproductive 97 
Toxicity of Biolabisia® in Rats 
3.3.1 Objectives 97 
3.3.2 Chemicals and experimental equipments 
3.3.3 Plant materials 
3.3.4 Animals 
3.3.5 Experimental protocol 
3.3.5.1 Histopathology of reproductive organs 
3.3.5.2 Parameters of study 
3.3.6 Statistical analysis 
97 
97 
97 
98 
100 
101 
104 
3.4 Main Study III: Evaluation on the Effects of Biolabisia® on 105 
Fertility and Implantation in Rats 
3.4.1 Objectives 105 
3.4.2 Chemicals and experimental equipments 
3.4.3 Plant materials 
3.4.4 Animals 
3.4.5 Experimental protocol 
3.4.5.1 Histopathology of reproductive organs 
3.4.5.2 Parameters of study 
3.4.6 Statistical analysis 
105 
105 
105 
106 
107 
109 
112 
3.5 Main Study IV: Evaluation of the Female Toxicity of 113 
Biolabisia® in Rats 
3.5.1 Objectives 113 
3.5.2 Chemicals and experimental equipments 113 
3.5.3 Plant materials 113 
3.5.4 Animals 113 
3.5.5 Experimental protocol 114 
3.5.5.1 Blood collection for hormonal analysis 115 
3.5.5.2 ELISA hormonal assay 115 
3.5.5.2.1 General principle of ELISA assay 115 
3.5.5.2.2 General procedure of ELISA 117 
assay 
3.5.5.2.3 ELISA assay reproducibility 119 
vii 
3.5.5.3 Histopathology of reproductive organs 
3.5.5.4 Parameters of study 
3.5.6 Statistical analysis 
CHAPTER FOUR : RESULTS 
120 
121 
124 
127 
4.1 Preliminary Study on the Effects of Aqueous Extract of LPA 127 
on Teratogenicity in Rats 
4.1.1 Authentication of plant materials and aqueous 127 
extraction of LPA 
4.1.2 General observation of health status of female rats 130 
4.1.3 Gross examination at autopsy 130 
4.1.4 Pregnancy outcomes 130 
4.1.5 Foetal observation 131 
4.2 Main Study I: Evaluation of the Teratogenicity of Biolabisia® 133 
in Rats 
4.2.1 Health status and fates of female rats 
4.2.2 Gross examination at autopsy 
4.2.3 Maternal body weight (MBW), weight gain and 
percentage changes in MBW 
4.2.4 Corrected maternal body weight (CMBW) 
133 
133 
135 
135 
4.2.5 Number of corpora lutea and implantation sites per 138 
litter 
4.2.6 Post-implantation death and resorption of conceptus 138 
4.2.7 Organ weights 138 
4.2.8 Histopathological findings 142 
4.2.9 Number of live foetuses per litter 145 
4.2.10 Sex distribution and foetal weight (male and female) 145 
4.2.11 External malformations 147 
4.3 Main Study II: Evaluation of the Female Reproductive 149 
Toxicity of Biolabisia® in Rats 
4.3.1 Health status and fates of female rats 149 
4.3.2 Gross examination at autopsy 
4.3.3 Maternal body weight (MBW), weight gain and 
percentage changes in MBW 
4.3.4 Oestrous cyclicity 
4.3.5 Mating index and duration of successful mating 
viii 
149 
151 
154 
154 
4.3.6 Pregnancy evaluations 
4.3.7 Implantation sites and post-implantation death 
4.3.8 Organ weights 
4.3.9 Gross and histopathological findings 
4.3.10 Body weight and growth rates of pups 
4.3.11 Pup evaluations 
164 
164 
164 
166 
169 
169 
4.4 Main Study III: Evaluation on the Effects of Biolabisia® on 172 
Fertility and Implantation in Rats 
4.4.1 General signs of toxicity of female rats 
4.4.2 Gross examination at autopsy 
172 
172 
4.4.3 Maternal body weight (MBW), weight gain and 172 
percentage change in MBW 
4.4.4 Corrected maternal body weight (CMBW) 173 
4.4.5 Oestrous cyclicity 176 
4.4.6 Organ weights 181 
4.4.7 Histopathological findings 181 
4.4.8 Number of corpora lutea, number of implantation 185 
sites and pre-implantation loss 
4.4.9 Post-implantation death and resorption of conceptus 185 
4.4.10 Number of live and dead foetuses per litter 189 
4.4.11 Foetal body weight and external malformations 189 
4.5 Main Study IV: Evaluation of the Female Toxicity of 190 
Biolabisia® in Rats 
4.5.1 General health and signs of toxicity 190 
4.5.2 Gross examination at autopsy 190 
4.5.3 Body weight, weight gain and percentage changes 190 
in body weight 
4.5.4 Oestrous cyclicity 
4.5.5 Organ weights 
4.5.6 Gross and histopathological findings 
4.5.7 Analysis of hormones 
ix 
193 
198 
198 
206 
CHAPTER FIVE: DISCUSSION 210 
5.1 Preliminary Study on the Effects of Aqueous Extract of LPA 213 
on Teratogenicity in Rats 
5.2 Main Study I: Evaluation of the Teratogenicity of Biolabisia® 215 
in Rats 
5.3 Main Study II: Evaluation of the Female Reproductive 221 
Toxicity of Biolabisia® in Rats 
5.4 Main Study III: Evaluation on the Effects of Biolabisia® on 228 
Fertility and Implantation in Rats 
5.5 Main Study IV: Evaluation of the Female Toxicity of 236 
Biolabisia® in Rats 
5.6 Overall discussion 247 
CHAPTER SIX: CONCLUSION AND RECOMMENDATIONS 
FOR FUTURE RESEARCH 
6.1 Conclusion 
6.2 Recommendations for future research 
BIBLIOGRAPHY 
APPENDICES 
Appendix 1 : Research and ethical committee approval 
Appendix 2 : Procedure of thin layer chromatography (TLC) 
Appendix 3 : General observation and behavioural changes 
chart 
Appendix 4 : Litter collection sheet 
Appendix 5 : Lists of publications and presentations 
Appendix 6 : Published papers 
Appendix 7 : Abstracts of scientific conferences and 
seminars 
x 
269 
269 
272 
275 
Table 
2.1 
3.1 
3.2 
3.3 
3.4 
3.5 
3.6 
3.7 
3.8 
4.1 
4.2 
4.3 
4.4 
4.5 
4.6 
4.7 
4.8 
LIST OF TABLES 
Comparison of guidelines and study designs where similar 
observations are made 
List of chemicals and laboratory equipments used in the 
preliminary study 
Qualitative parameters incorporated in histopathological 
examinations of ovary 
List of chemicals and laboratory equipments used in the 
Teratogenic study 
Qualitative parameters incorporated in histopathological 
examinations of uterus 
Qualitative and quantitative parameters incorporated In 
histopathological examinations of ovary and vagina 
Type of reagents and its respective volume for ELISA assay 
Qualitative and quantitative parameters incorporated in 
histopathological examinations of uterus 
List of chemicals and laboratory equipments used in the 
Female toxicity study 
Amount of aqueous extract of LPA obtained from 24 g of 
raw materials each in three different extractions 
Data of the preliminary study 
Maternal parameters of rats treated with Biolabisia® at 0, 2, 
20,200,400 and 1000 mg/kg/day from 06 through 016 pc 
Reproductive and foetal parameters of rats administered 
with various doses of Biolabisia® from 06 through 016 pc 
Maternal parameters of rats treated with Biolabisia® at pre-
mating, mating, gestation and lactation periods of seven 
days 
Oestrous cycle phases of rats during pre-treatment and 
while on treatment with Biolabisia® 
Pregnancy and reproductive parameters of rats treated with 
Biolabisia® at pre-mating, mating, gestation and lactation 
periods of seven days 
Foetal parameters of rats treated with Biolabisia® at pre-
mating, mating, gestation and lactation periods of seven 
days 
xi 
Page 
51 
76 
87 
93 
100 
111 
118 
120 
125 
129 
132 
137 
139 
153 
158 
165 
170 
4.9 Maternal and reproductive data of rats treated with 175 
Biolabisia® at pre-mating, mating and gestation periods 
lasting 15 days. 
4.10 Oestrous cycle phases of rats treated with Biolabisia® during 177 
pre-mating period for duration of two weeks. 
4.11 Reproductive organ weights and quantitative 182 
histopathological findings of females administered orally with 
Biolabisia® at pre-mating, mating and gestation periods of 
up to 015 pc. 
4.12 Reproductive and foetal data of animals treated orally with 188 
Biolabisia® at pre-mating, mating and gestation periods of 
up to 015 pc. 
4.13 Summary of observations on female rats after receiving 192 
daily administration of Biolabisia® for three weeks 
4.14 Oestrous cycle phases of rats treated with Biolabisia® for 194 
duration of three weeks 
4.15 Reproductive organ weights and quantitative 201 
histopathological data of females after receiving daily 
treatment of Biolabisia® for three weeks 
4.16 Serum hormone levels of rats during diestrus phase 207 
following three weeks Biolabisia® treatment 
xii 
LIST OF FIGURES 
Figure Page 
1.1 Flowchart of the study indicating important research activities 18 
3.1 Flowchart of LPA extraction in the preliminary study 63 
3.2 Experimental design of the preliminary study 74 
3.3 Experimental design of the Teratogenic study 90 
3.4 Experimental design of the Reproductive toxicity study 103 
3.5 Experimental design of the study 108 
3.6 Experimental design of the Female toxicity study 123 
4.1 Graph of the maternal body weights (MBW) in the 136 
Teratogenic study 
4.2 Graph of the maternal body weights (MBW) of treated and 152 
control groups of animals in the Reproductive toxicity study 
4.3 Graph of the maternal body weights (MBW) of treated and 174 
control groups of animals in the Fertility study 
4.4 Graph showing the body weights of treated and control 191 
groups of animals in the Female toxicity study 
4.5 Effects of three weeks Biolabisia® treatment on the serum 17- 208 
/3 oestradiol and progesterone levels of female rats in the 
Female toxicity study 
4.6 Bar chart presenting the free testosterone levels of female 209 
rats in the Female toxicity study 
xiii 
Plate 
2.1 
2.1 (a) 
2.1 (b) 
2.1 (c) 
2.1 (d) 
2.1 (e) 
4.1 
4.2 
4.3 
4.4 
4.5 
4.6 
4.7 
4.8 
4.9 
4.10 
4.11 
4.12 
LIST OF PLATES 
Labisia pumila (Blume) Fern.-Vill plant 
L. pumila flower 
L. pumila fruit 
L. pumila var. alata 
L. pumila var. pumila 
L. pumila var. lanceo/ata 
TLC chromatogram of ethanol extracts of LPA roots and 
leaves 
Macroscopic features of aqueous extract of LPA 
Photograph of normal pregnant dam from the control group 
during autopsy in the Teratogenic study 
Photograph of normal gravid uterus containing foetuses at 
021 pc from the 1000 mg/kg/day dose group in the 
Teratogenic study 
Photograph of cut-opened gravid uterus showing normal 
foetuses in the Teratogenic study 
Light photomicrographs of the ovary on 021 pc in the 
Teratogenic study 
Photograph of normal life foetuses with placenta attached 
from the Biolabisia® 2 mg/kg/day dose group in the 
Teratogenic study 
Photograph of a normal, still-breathing rat foetus without 
any external malformation from the control group in the 
Teratogenic study 
Photograph of visible normal implantation sites (scars) of 
the seventh day post partum uterus in the Reproductive 
Toxicity study 
A metestrus smears consisting of the same proportion 
among cornified, leukocytes and nucleated epithelial cells 
A diestrus smears primarily consisting of a predominance 
of leukocytes 
A proestrus smears consisting of abundant nucleated non-
cornified epithelial cells mostly arranged in "grape-like 
clusters" 
xiv 
Page 
32 
32 
32 
32 
32 
32 
128 
129 
134 
140 
141 
143 
146 
148 
150 
155 
155 
156 
4.13 An estrus smears indicating the presence of large 156 
anucleated cornified cells in the vaginal smear 
4.14 A sperm positive smears 157 
4.15 Photomicrographs of cross sectional uteri stained with 167 
H & E in the Reproductive toxicity study 
4.16 Photograph showing the specific external organs of pups 171 
used to make physical examinations to locate for any 
congenital malformation in the Reproductive toxicity study 
4.17 Photomicrographs showing the ovary on 016 pc in the 183 
Fertility study 
4.18 Photomicrographs showing a cross section of the vagina 184 
on 016 pc in the Fertility study 
4.19 Photograph of normal gravid uterus on 016 pc with 186 
foetuses enclosed in amniotic sac from the 200 mg/kg/day 
dose group in the Fertility study 
4.20 Photograph showing gravid uterus of rat with a resorption 187 
from the 20 mg/kg/day dose group in the Fertility study 
4.21 Histopathology of ovaries stained with H & E in the Female 202 
Toxicity study 
4.21 (e) Histopathology of ovary showing several cystic follicles 203 
(CF) in the Female toxicity study 
4.22 Photomicrographs of cross sectional uteri in the Female 204 
toxicity study 
4.23 Histopathology of vagina in the Female toxicity study 205 
xv 
ANOVA 
CFSAN 
CMBW 
o 
DCA 
Ddel 
Dkill 
OW 
E 
EU 
FBW 
FRIM 
FSH 
F. tes. 
g 
GMP 
GnRH 
GUW 
H&E 
HKL 
HUKM 
HUSM 
ICH 
IMR 
IQR 
KF 
kg 
LH 
LPA 
LD50 
LIST OF SYMBOLS AND ABBREVIATIONS 
Analysis of variance 
Center for Food Safety and Applied Nutrition 
Corrected maternal body weight 
Degree of Celcius 
Diestrus 
Drug Control Authority 
Day upon delivery 
Day upon sacrifice 
Distilled water 
Estrus 
European Union 
Female body weight 
Forest Research Institute of Malaysia 
Follicle stimulating hormone 
Free testosterone 
gram 
Good Manufacturing Practice 
Gonadotropin-releasing hormone 
Gravid uterine weight 
Haematoxylin and eosin 
Kuala Lumpur Hospital 
Hospital Universiti Kebangsaan Malaysia 
Hospital Universiti Sains Malaysia 
International Conference on Harmonization 
Institute for Medical Research 
Interquartile range 
Kacip Fatimah 
Kilogram 
Luteinizing hormone 
Labisia pumi/a var. a/ata 
Median lethal dose 
xvi 
LPL 
LPP 
M 
MARDI 
MBW 
mg 
ml 
MOH 
n 
NCTR 
NOAEL 
NPCB 
NRDHM 
OECD 
P 
pc 
Prog. 
SEM 
SO 
T/CM 
TLC 
UH 
UK 
UKM 
UM 
UMS 
UTM 
US 
USA 
USEPA 
USFDA 
Labisia pumi/a var. lanceo/ata 
Labisia pumi/a var. pumi/a 
Metestrus 
Malaysian Agricultural Research and Development 
Institute 
Maternal body weight 
milligram 
mi"ilitre 
Ministry of Health 
Sample size of animal 
National Center for Toxicological Research 
No observable adverse effect level 
National Pharmaceutical Control Bureau 
National Committee for Research and 
Development in Herbal Medicines 
Organization for Economic and Cooperation and 
Development 
Proestrus 
Post-coitus 
Progesterone 
Standard error of mean 
Sprague Dawley 
Traditional and complimentary medicine 
Thin layer chromatography 
Universiti Hospital, Universiti Malaya 
United kingdom 
Universiti Kebangsaan Malaysia 
Universiti Malaya 
Universiti Malaysia Sabah 
Universiti Teknologi Malaysia 
United States 
United State of America 
United States Environmental Protection Agency 
United States Food and Drug Administration 
xvii 
USM 
WHO 
11 ~-HSD1 
17 -13 oestradiol 
Universiti Sains Malaysia 
World Health Organization 
11 Beta Hydroxysteroid Dehydrogenase type 1 
17 -Beta oestrad iol 
xviii 
KAJIAN KETOKSIKAN REPRODUKTIF DAN PERTUMBUHAN EKSTRAK 
AIR Labisia pumila var. a/ata PADA TIKUS BETINA 
ABSTRAK 
Labisia pumi/a var. a/ata (LPA) atau Kacip Fatimah disenaraikan sebagai 
salah satu spesis utama oleh kerajaan Malaysia untuk dijalankan kajian saintifik 
pelbagai disiplin ke arah pembangunan ubatan herba tempatan berasaskan 
bukti saintifik. Kajian yang dihuraikan di dalam tesis ini adalah sebahagian 
daripada kajian pra klinikal ke atas LPA untuk menilai profil keselamatannya. 
Tujuan kajian ini adalah untuk menentukan potensi kesan sediaan komersial 
ekstrak air LPA ke atas ketoksikan reproduktif dan pertumbuhan pada tikus 
betina Sprague Dawley. Kajian permulaan dijalankan dengan menggunakan 
ekstrak air tidak terpiawai LPA pada dos 2, 20, 200 dan 400 mg/kg/hari. 
Sediaan komersial ekstrak air terpiawai LPA, didaftarkan sebagai Biolabisia® 
pad a dos 2, 20, 200, 400, 1000 mg/kg/hari atau air suling (kawalan) diberikan 
kepada tikus secara gavaging dalam kajian utama. Kajian Teratogenik 
dijalankan dengan memberikan rawatan Biolabisia® kepada tikus hamil semasa 
peringkat organogenesis. Rawatan ke atas tikus diberi sejak sebelum tempoh 
mengawan sehingga hari ke-7 waktu laktasi dalam kajian Ketoksikan 
reproduktif dan sebelum mengawan sehingga hari ke-15 kehamilan bagi kajian 
Kesuburan. Tikus dara diberikan rawatan dengan Biolabisia® selama tiga 
minggu dalam kajian ketoksikan am. Beberapa parameter reproduktif dan 
pertumbuhan dinilai di sepanjang tempoh kajian. Semua data numerikal 
dianalisa menggunakan SPSS versi 12.0.1. Keputusan diperolehi menunjukkan 
xix 
pemberian semua tahap dos Biolabisia® tidak menyebabkan kematian atau 
tanda-tanda ketoksikan yang ketara pada keadaan fizikal dan perlakuan 
keseluruhan tikus yang dikaji. Berat badan tikus betina menunjukkan corak 
perubahan yang sam a tetapi tiada keputusan yang signifikan di dalam semua 
eksperimen kecuali bagi penurunan signifikan berat badan dan berat badan 
sebenar ibu di dalam kajian Kesuburan. Rawatan dengan Biolabisia® tidak 
menyebabkan kesan teratogenik ke atas tikus di mana tiada fetus yang 
mempamerkan kecacatan kongenital luaran. Jumlah bilangan korpora lutea, 
bilangan tapak implantasi, peratus kehilangan embrio sebelum implantasi, 
peratus kematian embrio selepas implantasi, bilangan resorpsi fetus, bilangan 
fetus hidup, be rat badan fetus dan nisbah jantina fetus adalah setanding di 
kalangan semua kumpulan rawatan. Tempoh kitaran estrus dan berat organ 
reproduktif tidak terjejas oleh Biolabisia® secara statistik. Walaubagaimanapun, 
peningkatan bilangan tikus dengan kitaran estrus tidak teratur, kemunculan sis 
folikel ovari dan corak peningkatan aras hormon progesteron and testosterone 
bebas bagi kumpulan yang menerima dos Biolabisia® 1000 mg/kg/hari 
mencetuskan kebimbangan. Dengan mengambil kira semua data terkumpul, 
penemuan kajian ini mencadangkan bahawa rawatan oral Biolabisia® sehingga 
ke dos 1000 mg/kg/hari ke atas tikus betina tidak menunjukkan kesan 
ketoksikan yang signifikan. Walaubagaimanapun, berat badan dan kitaran 
estrus tikus berkemungkinan terjejas jika rawatan dengan Biolabisia® pad a dos 
tinggi diberikan untuk jangkamasa panjang. Penyelidikan berterusan 
menggunakan spes is haiwan bukan roden perlu dijalankan untuk 
melengkapkan profil keselamatan herba ini. 
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EVALUATION OF THE REPRODUCTIVE AND DEVELOPMENTAL 
TOXICITIES OF THE AQUEOUS EXTRACT OF 
Labisia pumila var. a/ata IN FEMALE RATS 
ABSTRACT 
Labisia pumi/a var, a/ala (LPA) or Kacip Fatimah has been listed by the 
government of Malaysia as one of the priority species for a multi-disciplinary 
scientific study towards the development of scientific, evidence-based herbal 
medicine. The present study described in this thesis is part of the preclinical 
assessment of LPA to evaluate its safety profile. The aims of this study were to 
evaluate the potential effects of aqueous extract of LPA on reproductive and 
developmental toxicities in Sprague Dawley rats. A preliminary study was 
conducted using unstandardised extract of LPA at 2, 20, 200 and 400 
mg/kg/day. Commercially prepared standard aqueous extract of LPA, registered 
as Biolabisia® at the doses of 2,20, 200,400, 1000 mg/kg/day or distilled water 
(control) were administered by gavaging to animals during the main studies. 
The Teratogenic study was conducted by treating pregnant animals with 
Biolabisia® during the period of organogenesis. Treatments of animals began 
from the time prior to mating until lactational periods of seven days in the 
Reproductive toxicity study and from before mating up to day 15 of pregnancy in 
the Fertility study. Virgin rats were treated with Biolabisia® for duration of three 
weeks in the Female toxicity study. A substantial number of reproductive and 
developmental parameters were assessed throughout this study. All numerical 
data were analysed using SPSS version 12.0.1. Results obtained indicated that 
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the administration of Biolabisia® at all dose levels did not cause mortality nor 
show noticeably any treatment-related signs of toxicity on the physical 
appearance and behaviour of all the rats studied. There was a consistent trend 
with body weight changes of females in all the experiments performed but they 
showed no significant differences except for the significant reduction in the 
actual and corrected maternal body weights of Biolabisia® -treated animals in 
the Fertility study. Treatment with Biolabisia® did not result in teratogenicity in 
rats since no foetus exhibited external congenital malformations. The total 
number of corpora lutea, number of implantation sites, percentages of pre-
implantation loss and post-implantation death, number of resorptions, number of 
live foetuses, foetal body weight and foetal sex ratio were comparable among 
all experimental groups. The length of oestrous cycles and reproductive organs 
weights of rats were statistically unaffected by Biolabisia®. However, high 
number of animals with irregular cycles, presence of ovarian follicular cysts and 
a trend of increased serum progesterone and free testosterone levels that were 
observed in the Biolabisia® 1000 mg/kg/day dose group do raised some 
concern. Taking all the cumulative data together, the current findings suggest 
that oral treatment of Biolabisia® of up to 1000 mg/kg/day in female rats is not 
associated with significant deleterious effects. However, the body weight and 
oestrous cycle of the females may be affected if higher doses of Biolabisia® are 
administered for a longer duration. Studies involving non-rodent animal species 
need to be performed to complete the safety profile of this herb. 
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CHAPTER ONE 
INTRODUCTION 
1.1 Preface 
During the 21 5t century, there has been an elevated level of hazardous 
risk due to xenobiotics and toxic substances towards the reproductive function 
of the human (Osamu, 2005). These groups of substances which include 
synthetics, naturally occurring chemicals, natural products, food additives, 
drugs, heavy metals, environmental pollutants, natural toxin and so forth have 
been included in the list of possible hazards (Sharara et al., 1998). Some of the 
substances are recognised (Hutz et al., 2006; Llanos and Ronco, 2009) and 
some are suspected (Sharara et al., 1998) as reproductive toxicants. Yet, there 
are still marketed products that use materials or chemicals, which have not 
been analyzed for its reproductive toxicity. 
In many instances, women are believed to be more vulnerable and at a 
higher risk than men in experiencing negative responses while being assessed 
with the reproductive effects of some of the aforementioned agents (Hoyer, 
2001; Butter, 2006; Vahter et al., 2007). Episodic exposure to high levels of 
some of these agents is responsible for the acute and chronic female 
reproductive and developmental health problems. Disorders of reproduction 
reported in females include infertility, menstrual disorders, reduction in libido, 
pregnancy complications, adverse outcomes of pregnancy, spontaneous 
abortion, low birth weight, heritable defects, premature reproductive 
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senescence, lactation disorders, various genetic diseases, and cancers (Daston 
et al., 1997; Drozdowsky and Whittaker, 1999; Hutz et aI., 2006). 
The prevailing risks from the above-mentioned inputs towards female 
reproductive health have caused much public concern and regarded as a 
relatively recent medical challenges raising considerable attention from 
scientific communities and legislators (Daston et al., 1997; Kimmel and Makris, 
2001). Stemming from conventional toxicology, this area of interest has evolved 
and ramified into a field known as female reproductive and developmental 
toxicology (Neubert et al., 1999a; Christian, 2001 c; Collins, 2006). 
In Malaysia, the field of reproductive toxicology is comparatively new as 
an area of research. To date, Malaysia is not a member in any of the 
international toxicological organization. Nevertheless, Malaysia through its 
Ministry of Health (MOH) has adapted various existing international guidance 
and has come out with its own regulation for conducting toxicological testing of 
materials (Ministry of Health Malaysia, 2003a). Researchers in this country are 
now ushering the community to take steps towards exploring this field upon 
realizing its enormous importance. These actions are genuinely taken in an 
attempt to improve the general health of the nation. Reproductive toxicology is 
currently experiencing a surge significance as there is a thrust in this area by 
the Malaysian government to encourage the production of high quality herbal 
products and nutraceuticals derived from local bioresources. The toxicological 
testings required in the development of these products will help to reduce public 
anxiety over the possible deleterious effects associated with herbal use. 
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1.2 Reproductive and developmental toxicology 
Toxicology is the study of poisons, their adverse effects on biological 
systems and methods of treatment for conditions they produce (Friis, 2006). 
The challenging science of toxicology has been in existence for many centuries. 
It has evolved from an expression of thoughts concerning poisons, victims and 
plants or chemicals as sources of ills to the current scientific discipline that it is. 
This field continues to establish and expand its principles into a range of sub-
specializations, for instance, reproductive and development toxicology, food and 
chemical toxicology, occupational medicine and industrial toxicology, forensic 
toxicology and so forth. All share one main goal that is to provide valuable 
information in the pursuit of ideals to protect people from harmful effects of 
hazardous agents (Borzelleca, 2001). Among the wide range of potential health 
risks, a prominent concern is that the agents may interfere with the functions of 
the reproductive system vis-a-vis reproductive and developmental toxicology. 
Reproductive and developmental toxicology investigate the effects of 
drug and other xenobiotics, which collectively show potential to impair human 
reproductive health. The consequences of even minor impairment during the 
reproductive process and / or during the development of the growing foetus can 
result in devastating outcomes to the organism (Miller et al., 2004). The 
complexity of component within the reproductive unit comprising the dam, sire 
and the progenies has driven the field of reproductive toxicology to be one of 
the vital scientific specialization recognised globally (Hoyer, 2001). According to 
Hayes (2001 a), reproductive toxicology is concerned with the causes, 
mechanism and sequelae of adverse effects of substances on the reproductive 
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process. The adverse effects may include alterations to the sexual organs and 
their functions, related endocrine regulation or pregnancy outcomes. They can 
be manifested as aberrations or modifications on sexual maturation, gamete 
production and transport, oestrous cycle, sexual behaviour, fertility, gestation, 
parturition, lactation, pregnancy outcomes and reproductive senescence 
(Christian, 2001 c). The field is separated into areas related to male and female 
fertility, and developmental toxicology (sometimes referred to as teratogenicity). 
Developmental toxicology is the study of the causes, mechanisms and 
sequelae of perturbed developmental events in species of animals that undergo 
ontogenesis. The affected endpoints include death, delayed / retarded 
development, dysmorphology and functional impairment (Hayes, 2001b). Based 
on these definitions, developmental toxicology is considered synonymous with 
"teratology". Special emphasis is put on the developing conceptus, which 
include the development and function of that conceptus throughout its entire 
lifespan (Christian, 2001c). This field can be further narrowed down into 
prenatal and postnatal toxicology (Hayes, 2001c). 
Presently toxicological evaluation and regulations of chemicals referred 
earlier were developed and reviewed as a consequence of three human 
tragedies that resulted from in utero exposure to drugs; (i) thalidomide -
congenital malformations, (ii) Minimata disease - behavioural/functional 
alterations and (iii) diethylstilbestrol (DES) - cancer (Christian, 2001 c). Before 
the "Thalidomide disaster" (1959-1962), no routine toxicological evaluation of 
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chemicals and drugs on reproduction and development was carried out 
(Neubert et al., 1999a). 
Only in mid-1960s, the systematic preclinical studies of the possible 
adverse effects on reproduction and development necessitated the need for the 
registration of new pharmaceutical products and certain types of 
environmentally occurring chemicals, such as pesticides (Neubert et al., 1999a). 
However, the regulatory research and testing guidelines needed to be reviewed 
and improved especially after the first and second outbreak of Minimata disease 
in 1956 and 1965. This occurrence has increased concerns regarding adverse 
effects of highly toxic chemicals that can cause severe health problems and 
death to people and animals. Furthermore, cancer that resulted from exposure 
to DES in early 1970s has once again raised additional attention concerning 
deleterious effects that were not noticeable until after puberty. Thus, a broad 
range of endpoints in guidelines was required to evaluate various aspects of 
potential reproductive toxicity (Christian, 2001c). 
1.3 Herbal medicine 
Herbal medicine (phytomedicine / botanical medicine) constitutes one of 
the leading complementary therapies in this century. It is a common component 
in Ayurveda, pharmacotherapy, homeopathy, naturopathy and so forth. It refers 
to the use of finished, labelled medicinal products that contain active ingredients 
of aerial or underground parts of plants, or other plant material, or combinations, 
whether in the crude form or as plant preparations for the purposes of 
maintaining and the healing of various health conditions. Herbal medicines may 
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contain excipients in addition to the active ingredients. Medicines containing 
plant material combined with chemically defined substances are however, not 
considered to be herbal medicines (World Health Organization, 1996). The 
utilisation of herbs as medicine started since time immemorial. Its contributions 
in maintaining human health is very impressive and well recognised globally. 
The World Health Organisation (WHO) estimated that 80% of the world 
population rely on it for their health care needs (Shrivastava et a/., 2007). 
In recent years, we are witnessing enormous public interests in the use 
of herbal remedies despite the advancement of modern medicine. The 
popularity of herbs is experiencing a renewed resurgence with new approaches 
and use. According to WHO, the herbal usage throughout the world exceeds 
that of the conventional drugs by two to three times (Pal and Shukla, 2003). The 
numerous varieties of herbal products in the market are testimony of the current 
upward trend in its use. They have been widely consumed as alternative 
medicines in conjunction with conventional synthetic drugs to treat a variety of 
medical conditions and reverse the progression of health disorders (Kamboj, 
2000; Erah, 2002) including premature aging, obesity, body weakness, sexual 
dysfunction, menopause, women's problem, chronic diseases et cetera. 
For various reasons, people often turn to herbal medicines when their 
long-lasting illness could not be cured by conventional medicine, also when 
these products can satisfy their needs and show no untoward side effects (Pal 
and Shukla, 2003). Herbal remedies are not only used in the prevention and 
treatment of diseases but are also utilized as alternative approaches to enhance 
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overall well being while they are still in a good health. The healing power of 
herbs is thought to sooth the soul and help people feel better and live longer 
due to the naturally derived substances present in them (Kamboj, 2000; Abas, 
2001; Seeft, 2009). Moreover, the lower costs and the ease of self-medication 
with herbal products when compared to synthetic medicine give people a 
perceived ability to personally control their health (Pal and Shukla, 2003). Apart 
from the above, the holistic practices that is associated with herbal medicine like 
prayers (doa), incantation Oampi), abstinence (pantang) and other practices 
make the process of rehabilitation and health promotion alive and real (Zakaria 
and Mohd, 1994; Haliza, 2000). Additionally, the believe that herbal medicines 
are natural products and are therefore safe also contribute to their popularity 
(Abas, 2001; Niggemann and Gruber, 2003). Although, the fact remains that the 
safety of plant materials can only be established upon proper scientific studies. 
In Malaysia, the government realizes and draws attention to the huge 
contribution of herbal medicines both in the traditional and complementary 
medical systems. The government has in stages actively providing the direction 
for the country in relation to the implementation of strategies, formulation of 
action plans and programmes, research and development related to herbs. All 
efforts are now focused towards establishing herbal industry at international 
level. This becomes one of the main agenda in the eighth Malaysian 
Development Plan (Ministry of Agriculture Malaysia, 2000; Ministry of Health 
Malaysia, 2000). These are expected to help spearhead, improve and sustain 
the herbal industry as an important economic contributor to the nation's coffers. 
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1.3.1 Safety issue of herbal medicine 
Safety is one of the consumer's basic rights, It is defined as the right to 
be protected against the marketing of goods or provisions of services that are 
hazardous to health and life (Mohan, 2001). Although there has been a huge 
escalation in the use of herbs in our country and the world, the scientific input to 
backup their usage are still lacking. The quality, safety and efficacy of these 
products remain the main issues of relevance (Erah, 2002; Barnes, 2003). The 
concern for toxic side effects, their efficacy and limitations must be given 
serious attention and should not be taken for granted just because they are 
natural. 
Normally medicinal herbs contain potent, bioactive compounds. Many of 
their pharmacological effects remain unidentified (Abas, 2001; Zakiah, 2001; 
Barnes, 2003). In fact, their chemical constituents are far from being studied 
thoroughly. This situation gets complicated when herbal preparations are mixed 
with other known active ingredients (Erah, 2002) and when they are used as a 
complement to conventional medicine. As known widely, the preparation and 
formulation of herbal remedies is different to that of pharmaceutical synthetic 
medicine. Even if they are now available in the forms of capsule, pills and oral 
dosage forms but they are not scientifically prescribed by regulatory bodies and 
the information on their efficacy, appropriate dosages and drug interactions are 
poorly understood (Abas, 2001; Barnes, 2003). Therefore, they should be used 
with caution and while they are relatively safe when taken properly as 
preventive agents and for the promotion of health rather than strictly for healing. 
8 
Scientific evidence to justify their safety is much awaited (Abas, 2001; Mohsin, 
2005). 
Apart from the above, most of herbal preparation is not properly 
standardised by scientific accredited methods. Standardisation of these 
products is of particular importance to ensure their therapeutic efficacy (Azizol 
and Rasadah, 2000). Most of the herbal products available in Malaysia are not 
assessed for purity and consistency of active compound and this led to 
misidentification, substitution and adulteration. These could be due to the 
addition of incorrect species, altered mixtures of species, intentional or 
unintentional inclusion of allergens, pollen, insect parts, heavy metals such as 
lead, mercury and arsenic (Seeff, 2009) and scheduled poisons (drugs) (Abas, 
2001). Therefore, a proper approach that allows highly precise standardisation 
both chemically and biologically need to be put forward (Hylands, 2001). 
Meanwhile, detailed toxicity and safety assessments of medicinal products and 
subsequently the clinical trial must be performed to assure their safety and 
efficacy for human consumption. 
As the years go by, concern and awareness of any hazardous effects 
derived from the utilization of herbs among consumers and clinical practitioners 
are rising. This is a positive scenario where it will encourage the production of 
safer and high quality herbal products. As emphasized in the WHO guidelines, 
herbal medicine should be required to undergo toxicology testing in order to 
verify their safety when used on the human (World Health Organization, 1998). 
Since 1992, Malaysia through its Drug Control Authority (DCA) acting via its 
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secretariat, the NPCB has implemented regulatory measures to ensure the 
quality and safety of any traditional products sent to them for approval and 
registration. The registered products falling into the list of items under this 
regulation are expected to be prepared in a scientific manner and comply with 
the Good Manufacturing Practice (GMP) requirements. Nonetheless, such 
products are only labelled as cures for general illness and not for treatment of 
specific disease due to the lack of scientific data to support the claims of their 
efficacy (Zakiah, 1999). 
The dearth of detailed scientific information on the safety and efficacy of 
herbal products are one of the major problem faced in our country. Indeed, 
knowledge of their pharmacological properties and chemical constituents are 
very limited in the literature. The pace of scientific advancement shows an 
imbalance with the trend of herbal use. Hypothesis, assumptions and claims are 
definitely not good enough for these products to gain support and acceptance 
amongst professionals. The importance of the need for scientific research to be 
carried out by trained scientists is a fact that cannot be denied. The application 
of science and technology is vital indeed in the mission of transforming 
ambiguous traditional preparations into modern authenticated pharmaceutical 
products. Furthermore, systematic documentation and scientific explanation for 
their properties as medicinals, are urgently needed and are of the utmost 
importance in order to provide us with valuable and appropriate references on 
local herbs. 
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1.3.2 Labisia pumila (Blume) Fern.-Vill 
One of the most popular herbs that is receiving high demand by the local 
populace in Malaysia is Labisia pumila or locally known as Kacip Fatimah (KF). 
The term KF is used to describe the plant L. pumila in general. There are at 
least four known varieties of L. pumila found in Malaysia (Stone, 1988; Mohd 
Noh et aI., 2002). Though, only three of them are popularly used by the Malays 
and these are L. pumila var. pumila (LPP), L. pumila var. a/ata (LPA) and L. 
pumila var. lanceolata (LPL) (Stone, 1988). 
If Tongkat Ali (Eurycoma 10 ngifolia) is supposed to benefit the male 
species, L. pumila is closely associated to women and therefore thought to 
benefit the female. It has been utilized by the Malays and aboriginal women of 
reproductive age for numerous purposes. These include the balancing of bodily 
function, promotion of women's health and as a sexual stimulant. According to 
elderly Malays, this herb is a compulsory ingredient in most of the traditional 
herbal preparation since it is believed that L. pumila could improve the 
effectiveness of the other herbal products (Zainon, 2004). Traditionally, water 
decoctions of the root or whole plant have been given to pregnant woman prior 
to childbirth for the main purpose of inducing and facilitating labour (Stone, 
1988; Jamia et aI., 1999a; Jaganath and Ng, 2000). It is also used as a 
postpartum medication (Stone, 1988) in the form of mixed preparation to help in 
the recovery of the post-gravid uterus. It is thought that the herb could 
normalise the size and function of this organ in a shorter period than the 
average of six weeks seen in normal mothers (Muhamad and Mustafa, 1994; 
Yoga, 2003). Further, L. pumila is reported to extend fertility, to regularize blood 
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circulation and to help regain body strength of postpartum mothers (Muhamad 
and Mustafa, 1994). Its other folkloric uses include treatment of dysentery, 
flatulence, dysmenorrhoea, gonorrhoea, rheumatism, haemorrhoid and help to 
firm and tone the abdominal muscles (Jamia et a/., 1999b; Jaganath and Ng, 
2000). Other than that, many believe that this herb is able to enhance libido 
(Asiah et aI., 2007), alleviate fatigue and promote emotional well being. Thus, it 
is always recommended to women who have less interest in sex. Furthermore, 
it is also claimed as a phytoestrogen and therefore may assist women in 
achieving fuller breasts and can tighten vaginal muscles (Yoga, 2003; Ayida et 
al., 2006). 
The popularity of L. pumila is manifested by the emergence of many 
commercial products in the Malaysian market. These come in many forms 
including capsules, tablets, canned drinks and instant tea or coffee containing 
this herb. These products are claimed to contain the ground or extracted parts 
of the plant (Houghton et al., 1999; Wan Nazaimoon, 2002). Moreover, these 
products are widely advertised by various advertising media. In fact, the 
popularity of L. pumila is not only amongst Malays but other races as well. 
Nevertheless up to the year 2002, there were no standardised preparation or 
scientific data authenticating or evaluating the quality, safety and efficacy of this 
herb (Houghton et al., 1999). In addition, little is known of the chemical 
constituents of this plant. 
Recognizing the importance and commercial potential of L. pumila as a 
high quality herbal product or nutraceutical, the Government of Malaysia had 
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identified this herb as one of the priority species for a multi-disciplinary scientific 
research. The research started in 2002, as part of the National Natural Product 
Biotechnology Programme and funded by the National Biotechnology 
Directorate under the Ministry of Science, Technology and Innovation (MOSTI). 
Funding allocations are from the Ministry's Intensive Research on Priority Areas 
of the eighth Malaysian Development Plan. Several universities and research 
institutions, i.e. Institute for Medical Research (IMR), Forest Research Institute 
of Malaysia (FRIM), Universiti Sains Malaysia (USM), Universiti Kebangsaan 
Malaysia (UKM), Universiti Malaysia Sabah (UMS) and so forth are involved in 
this research. The groups' objectives are summarised into five main efforts: 
i) Sourcing and propagation of L. pumila - FRIM, UMS 
ii) Standardisation of crude and formulated L. pumila - UKM 
iii) Estrogenic and androgenic activities of L. pumila - IMR, HUKM 
iv) General and reproductive toxicology of L. pumila - IMR, USM 
v) Clinical trials (phase 1,2, 3) on L. pumila - IMR, HUSM, HUKM, 
MOH, UH, HKL, 
Ipoh Hospital. 
(Wan Nazaimoon, 2002; IMR, 2003) 
The present study is the effort of the fourth group above and is intended 
to complement the overall documentation of L. pumila. 
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1.4 Scope of the study 
The present study was designed to assess the possible reproductive, 
developmental and female toxicities of LPA using animal model. The LPA 
chosen is the most commonly used by the Malay community in the country 
(Jamia et al., 2004) and can be easily obtained throughout the region. The type 
and method of extract preparation as well as the route of administration in this 
study were applied based on the traditional ways. This is to mimic the human 
practices as close as possible and to induce similar effects in the animal model. 
The decision to undertake this study is due to the fact that this herb is popular 
and has been used as a natural remedy for female reproductive problems. 
Couple to the above information, the lack of data on its safety make the 
intention of this study all the more important. 
A set of study comprising of a preliminary experiment and four main 
studies were conducted in rats, as the best animal model for this study. Prior to 
the commencement of the main study, a preliminary evaluation of teratogenicity 
was conducted using self-prepared, unstandardised aqueous extract of LPA. 
The main studies were subsequently performed as described below using 
commercially prepared standard aqueous extract of LPA, registered with the 
National Pharmaceutical Control Bureau (NPCB) as the trade name of 
Biolabisia®. The studies are listed as follows: 
(a) "Evaluation of the Teratogenicity of Biolabisia® in Rats" (hereinafter 
referred as "Teratogenic study"). This study was designed to screen the 
teratogenic potential of the herb when it is administered during the 
organogenesis period. 
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(b) "Evaluation of the Female Reproductive Toxicity of Biolabisia® in Rats" 
(hereinafter referred as "Reproductive toxicity study"). This study was 
designed to screen the effects of the herb on reproductive function and 
to mimic the traditional consumption of L. pumila during the reproductive 
period, at the end of pregnancy (Stone, 1988; Jaganath and Ng, 2000) 
and during confinement and breastfeeding (Stone, 1988). 
(c) "Evaluation on the Effects of Biolabisia® on Fertility and Implantation in 
Rats" (hereinafter referred as "Fertility study"). The design of this study 
was to evaluate the effects of the herb on initiation of pregnancy and to 
make a representation of the period where usage of L. pumila in human 
continued into the early pregnancy period while the pregnant mother is 
not aware of the pregnancy. 
(d) "Evaluation of the Female Toxicity of Biolabisia® in Rats" (hereinafter 
referred as "Female toxicity study"). This study was designed to 
evaluate the effects of the herb during non-pregnancy state and to 
reflect on conditions where L. pumila is consumed by women during the 
peri menopausal period and in between pregnancies for energy gain 
and for the sustenance of their reproductive health. 
The results obtained from these experiments are expected to provide 
useful information on the type and degree of toxicities of L. pumila on 
reproductive system in rodent. The collection of data in this study is meant to 
provide some basis for the development of the safety profile of this herb and 
thereby help to alleviate concerns over its possible toxicity. Further, studies 
using a second animal species, preferably non-rodent like rabbits for evaluation 
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of teratogenicity (ICH-S5A, 1994; OECD, 2001; Janer et al., 2008) and 
monkeys for female toxicity study (Chahoud, 2004), need to be undertaken in 
order to complete the investigation of reproductive toxicity of L. pumila in animal 
models. 
1.4.1 Test procedures and guidelines used 
The designs and methods used in performing the female reproductive 
and developmental toxicity studies as described in this thesis were adapted 
from current internationally accepted guidelines (OECD, 1983; ICH Steering 
Committee, 1993; WHO Regional Office for the Western Pacific, 1993; Manson 
and Kang, 1994a; U.S. Food and Drug Administration, 2000b; U.S. Food and 
Drug Administration, 2000a; Christian, 2001 c; OECD, 2001). These guidelines 
were efforts of the World Health Organization (WHO), Organization for 
Economic and Co-operation and Development (OECD), United States Food and 
Drug Administration (U.S FDA) and International Conference on Harmonization 
(ICH). Basically, all organizations address a similar standard guideline. Even 
though each guideline is presented in its own way and approaches, all aspects 
of reproductive and developmental toxicity testing are covered. These include 
various study designs and evaluation endpoints as summarized within the 
guidelines. Information of each organization and regulatory guidelines will be 
elaborated in Chapter Two (subchapter 2.5) of the current thesis. 
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1.5 Objectives 
1.5.1 General objectives 
The general objectives of the present study were to evaluate the 
potential effects of Biolabisia® on female reproductive system and development 
of progenies in rats. This study is a part of the ultimate goal in an effort towards 
establishing reliable safety profiles for the herb using animal model (rodent). 
1.5.2 Specific objectives 
The specific objectives of this study are listed below: 
I. To prepare the aqueous extract of LPA and to determine 
the appropriate dose range required for the elucidation of 
the potential toxicity of the extract on female reproductive 
system in rats through a preliminary study. 
ii. To evaluate the teratogenic potential of commercially 
prepared LPA (Biolabisia®) in pregnant rats by means of 
the Teratogenic study. 
iii. To evaluate the effects of Biolabisia® on reproductive 
toxicity of pregnant rats via the Reproductive toxicity study. 
iv. To assess the effects of Biolabisia® on fertility and 
progression of implantation in pregnant rats by means of 
the Fertility study. 
v. To assess the potential female toxicity of Biolabisia® in non-
pregnant rats via the Female toxicity study. 
The research strategy of this study is indicated in Figure 1.1. 
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Discussion with the supervisor and research team on 
research activities. 
Preparation of aqueous extract of LPA for the preliminary 
study. 
l 
Preliminary study on the effects of aqueous extract of LPA 
on teratogenicity in rats. 
1 
1 1 
Screening studies: Definitive studies: 
1. Evaluation of the 3. Evaluation of the effects 
teratogenicity of of Biolabisia® on fertility 
Biolabisia® in rats. and implantation in rats. 
2. Evaluation of the female 4. Evaluation of the female 
reproductive toxicity of toxicity of Biolabisia® in 
Biolabisia® in rats. rats. 
Figure 1.1 Flowchart of the study indicating important research activities 
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1.6 Importance of the study 
The evolution of scientific methodologies in herbal research uncovers 
huge potential of developing medicinal herbs into therapeutic agents and other 
health related chemical entities. Concurrently, the present research step up 
emphasizes quality and safety issues of Biolabisia® that are paramount in 
ensuring its safety. This research is expected to help establish relevant safety 
profile and provide assessment of the potential toxicities of this herb during its 
development as a herbal medicinal product. 
Data regarding the adverse effects of L. pumila in human has not been 
reported while no scientific work was ever attempted to investigate the 
toxicology of this popular herb in the female reproductive system. The limited 
scientific literature pertaining to its quality, safety and efficacy enhance the 
urgency of conducting this present research. Information gathered could be 
utilized as an initial scientific platform for the scientific community in particular, 
as well as for the general public in general. Further, this research can be a 
basis for the initiation of other related works investigating the potential 
toxicological effects of other herbal preparations on female reproductive system. 
This is especially pertinent for the Malaysian scenario. 
Apart from expanding new knowledge regarding this herb, the present 
research can also indirectly enlighten consumers about L. pumila and help to 
alleviate fear or apprehension in using Biolabisia® as an alternative to the 
synthetically produced pharmaceutical drugs. This is particularly so in relation to 
the promotion of women's health. The confidence and support from the public 
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and professionals can inspire greater awareness and therefore help to improve 
the herbal market on one hand while creating a stronger public demand for safe 
products. This can also be a driving force for the development of newer safer 
herbal medicines from the relatively rich, unexplored plant resources of 
Malaysia. 
Alternatively, the science of reproductive and developmental toxicology 
applied in this study can also help in ensuring better understanding among 
Malaysian researchers, while the need to establish adequate number of 
expertise in this field is also becoming more urgent in Malaysia. In essence, the 
development of new knowledge concerning potential hazards of consumer 
products like herbal preparation will ultimately help protect the well-being of the 
public via improved public health delivery. 
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CHAPTER TWO 
LITERATURE REVIEW 
2.1 Medicinal plants in Malaysia 
The home to the world's richest biodiversity is widely recognized as 
being located in the tropical regions (Bodeker, 2000). Nearly 35,000 to 70,000 
species out of the estimated 422,000 flowering plant species in the world are 
used for medicinal purposes. Out of this, at least 6,500 plant species had been 
reported to have therapeutic properties are found in Asia. This makes Asia as 
one of the largest biodiversity region of the world. Six of the world's 18 
megabiodiversity hot spots are situated in Asia. These include the Eastern 
Himalaya, North Borneo, Peninsular Malaysia, Sri Lanka, Philippines and the 
Western Ghats of South India. All these areas are known as the concentrated 
area of flora species richness (Handa, 2005). 
Malaysia is blessed with exceedingly rich and diverse bioresources 
potentials. In fact, the Malaysian tropical rain forest that evolved over 100 
million years is one of the oldest and complex biological ecosystems in the 
globe (Suhaimi et 81., 2001). These natural assets feed various industries and 
have become the provider of natural resources chemical entities and biomass 
for herbal, pharmaceutical, nutraceutical, pure phytochemical, cosmeceutical, 
agrochemical industries et cetera. 
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A figure by EarthTrends Country Profiles (2003) indicated that a total 
number of known higher plants in Malaysia from year 1992 to 2002 is 15,500 
species. Bidin and Latiff (1995) and Parris and Latiff (1997) reported that the 
flora of Malaysia is estimated to number around 15,000 species of flowering 
plants and more than 1,170 species of ferns and fern allies. Peninsular 
Malaysia alone is host to approximately 7539 species from 1510 genera of 
flowering plants, 632 of ferns and fern-allies species and 27 of gymnosperms 
species (Bidin and Latiff, 1995; Turner, 1995). Of these, about 1,200 species or 
8% of the total flora has been used in various traditional medicinal practices 
(Soepadmo, 1999). However, these numbers do not include the species found 
in East Malaysia, which is believed to have some unique species only found in 
that region. Sadly there is no known published exhaustive checklist of the 
medicinal plants found in Sabah and Sarawak (Soepadmo, 1999; Kamarudin 
and Latiff, 2002). 
Since the past decades, the rural communities in Malaysia have been 
proud of the role and contribution of medicinal plants as a source of their 
traditional care systems, sustenance as well as in the production of herbal 
medicinal products. It is estimated that 17.1% and 29.6% of Malaysian utilised 
medicinal plants to treat their health problems and for health maintenance 
respectively (Azriani et al., 2008a). Various groups such as Malay, Chinese, 
Indian, the aborigines (Orang Asli) and other ethnic groups of Sabah and 
Sarawak (Kadazan, Dusun, Iban, Bajau and so forth) have been identified as 
the major consumers of medicinal plants (Mohd Azmi and Norini, 2001). Plant 
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parts used for remedies include the roots, leaves, barks, seeds, flowers and 
fruits (Haliza, 1994; Mohd Azmi and Norini, 2001). 
The indigenous knowledge on medicine is mainly obtained through 
heritage where the information is being passed over from generation to the next 
generation (Halijah et al., 2005) through verbal or practices. Sometimes, the 
knowledge is acquired from the traditional healers through special asceticism 
(Haliza, 2000). However, the spread of information was slow and private among 
small groups of people, which makes it difficult until now to find any manuscript 
written by these traditional practitioners regarding the utilization of medicinal 
plants. The Malay traditional healers are more comfortable to claim that their 
knowledge are exclusive for their use or to be past down to members of their 
family only (Mohsin, 2006). However, there is one Malay historical manuscript 
namely the "Tajul Muluk" which describes ingredients of Malay traditional 
medicine used by the ancient kings. But there is no thorough scientific 
investigation of its contents nor any academic discourse as to how far it had 
been referred to by other traditional practitioners in this country (Siti Amrah, 
2004). 
According to Kamarudin and Latiff (2002), for more than 50 years, the 
books by Burkill and associates such as the "Malay Village Medicine" by Burkill 
and Haniff (year 1930) and "A Dictionary of the Economic Products of the Malay 
Peninsula" by Burkill (year 1935) were the only published reference available on 
Malaysian medicinal plants in this region. Since then, not much studies or new 
data collection were carried out. However, in the mid-1970s there has been a 
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resurgence of interest amongst young academics and researchers at the UKM, 
Universiti Malaya (UM) and local research institutions on medicinal plants. 
Realizing the importance of scientific research in this field, a multidiscipline 
research team namely "Kumpulan Penyelidikan Ubatan Tradisional" or 
"KUBATRA" in short, was subsequently set up in UKM in the early 1980s 
(Kamarudin and Latiff, 2002). 
KUBATRA has inspired the formation of other research groups, which 
consisted of researchers and scientists from other universities. In 1985, 
"Kumpulan Penyelidik Sebatian Semulajadi Malaysia" was set up and 
subsequently developed into an established formal team namely "Persatuan 
Sebatian Semulajadi Malaysia" in 1997. This organization spearheaded and 
coordinated many annual research activities related to medicinal plants with 
multidisciplinary approaches towards utilization, conservation and development 
of safe, efficacious and quality products derived from medicinal plants. The 
research activities included seminar, workshop, conference, forum and 
publication that involved local and international researchers, academicians, 
government, private sector, entrepreneurs and policy makers (Siti Amrah, 
2004). 
Presently, the government has taken many steps to encourage advance 
scientific research, standardisation and introduction of new technology in the 
quality control procedures related to medicinal plants. These efforts were 
promoted while not ignoring aspects of conservation, good methodology, 
cultivation and legislation relevant to the development of the herbal and 
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